Vertex Licenses VX-944 to Avalon for Development and Commercialization

Vertex Pharmaceuticals and Avalon Pharmaceuticals have announced that they have entered into a licensing agreement for the development of the investigational agent VX-944 in oncology indications. Under the terms of the agreement, Avalon will hold exclusive rights to develop and commercialize VX-944 worldwide for the treatment of various cancers.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/02-15-2005/0003021767&EDATE=)